Medtronic is the global healthcare technology leader that boldly attacks the most challenging health problems. Medtronic’s Mission — to alleviate pain, restore health, and extend life — unites a global team of more than 90,000 passionate people across 150 countries. The Norwegian office in Skøyen in Oslo employs about 50 people. Medtronic technologies and therapies treat more than 70 health conditions in Cardiovascular, Medical Surgical, Neuroscience and Diabetes – and transform the lives of two people every second, every hour, every day. In everything Medtronic does, it is engineering the extraordinary.
Merck, a leading science and technology company, operates across healthcare, life science and performance materials. Globally, 57,000 employees work to make a difference in people’s lives; from advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices.
Merck was founded in 1668. The family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials.
Bayer is a Life Science company with a more than 150-year history and core competencies in the areas of health care and agriculture. With its focus on preventing, alleviating, and treating diseases and providing a reliable supply of high quality food, feed, and plant-based raw materials, Bayer’s innovative products are contributing to finding solutions to some of the major challenges of our time – reflecting the company’s purpose, science for a better life. Bayer Norway is headquartered in Oslo and employs 155 people. Bayer’s vision is: Health for all, Hunger for none.
Sanofi has been leading pharmaceutical innovation for over 100 years. Globally, the company has more than 100,000 employees in over 100 countries and is headquartered in Paris, France. Sanofi is organized into five global units, and their work in Norway is focused on four different therapeutic areas: primary care, consumer healthcare, specialty care, and vaccines. Sanofi-Aventis’ Norway branch is in Lysaker and employs 82 people.
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com or astrazeneca.no and follow the Company on Twitter @AstraZeneca.
Boehringer Ingelheim is one of the world’s 20 leading pharmaceutical companies. For more than 130 years, the family-owned company has developed new medicines for people and animals. Boehringer Ingelheim’s nearly 50,000 employees work to implement the company’s mission to spread value through innovation in three core areas: human medicine, veterinary medicine, and biopharmaceutical contract-based production. The company demonstrates its social responsibility by actively participating in the “Making More Health” initiative and prioritizing environmental protection and sustainability in all levels of operation. In Norway, Boehringer Ingelheim employs 71 people. In 2018, Boehringer Ingelheim’s Norwegian Branch achieved a total net sales revenue of NOK 423,000,000.
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics, and is focused on advancing research programs in multiple sclerosis and neuroimmunology, Alzheimer’s disease and dementia, neuromuscular disorders, movement disorders, ophthalmology, immunology, neurocognitive disorders, acute neurology, and pain.